Eterna (ERNA) Therapeutics announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company’s scientific advisory board. With their deep insight and experience in cell therapy, Dr. Zeldis and Dr. Blythe will play a role in advancing ERNA-101 in solid tumors and ERNA-102 in autoimmune diseases through their preclinical studies.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA: